000 | 01926 a2200565 4500 | ||
---|---|---|---|
005 | 20250513205436.0 | ||
264 | 0 | _c20000419 | |
008 | 200004s 0 0 eng d | ||
022 | _a0007-0920 | ||
024 | 7 |
_a10.1054/bjoc.1999.1087 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aRiccardi, A | |
245 | 0 | 0 |
_aLong-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. _h[electronic resource] |
260 |
_bBritish journal of cancer _cApr 2000 |
||
300 |
_a1254-60 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
650 | 0 | 4 | _aDisease Progression |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aMelphalan _xadministration & dosage |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMultiple Myeloma _xdrug therapy |
650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aSurvival Analysis |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aMora, O | |
700 | 1 | _aTinelli, C | |
700 | 1 | _aValentini, D | |
700 | 1 | _aBrugnatelli, S | |
700 | 1 | _aSpanedda, R | |
700 | 1 | _aDe Paoli, A | |
700 | 1 | _aBarbarano, L | |
700 | 1 | _aDi Stasi, M | |
700 | 1 | _aGiordano, M | |
700 | 1 | _aDelfini, C | |
700 | 1 | _aNicoletti, G | |
700 | 1 | _aBergonzi, C | |
700 | 1 | _aRinaldi, E | |
700 | 1 | _aPiccinini, L | |
700 | 1 | _aAscari, E | |
773 | 0 |
_tBritish journal of cancer _gvol. 82 _gno. 7 _gp. 1254-60 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1054/bjoc.1999.1087 _zAvailable from publisher's website |
999 |
_c10708731 _d10708731 |